0TDF Stock Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
Roche Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF30.78 |
52 Week High | CHF40.26 |
52 Week Low | CHF30.02 |
Beta | 0.15 |
1 Month Change | -6.44% |
3 Month Change | -12.98% |
1 Year Change | -19.76% |
3 Year Change | -26.20% |
5 Year Change | -5.99% |
Change since IPO | -0.36% |
Recent News & Updates
Recent updates
Shareholder Returns
0TDF | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | -0.3% | 2.5% | 0.4% |
1Y | -19.8% | -3.7% | -1.0% |
Return vs Industry: 0TDF underperformed the UK Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: 0TDF underperformed the UK Market which returned -1% over the past year.
Price Volatility
0TDF volatility | |
---|---|
0TDF Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 8.7% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0TDF has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0TDF's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1896 | 103,605 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas.
Roche Holding AG Fundamentals Summary
0TDF fundamental statistics | |
---|---|
Market cap | US$195.63b |
Earnings (TTM) | US$12.61b |
Revenue (TTM) | US$66.31b |
15.4x
P/E Ratio2.9x
P/S RatioIs 0TDF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0TDF income statement (TTM) | |
---|---|
Revenue | CHF60.44b |
Cost of Revenue | CHF15.60b |
Gross Profit | CHF44.84b |
Other Expenses | CHF33.35b |
Earnings | CHF11.50b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 14.42 |
Gross Margin | 74.19% |
Net Profit Margin | 19.02% |
Debt/Equity Ratio | 88.0% |
How did 0TDF perform over the long term?
See historical performance and comparison